The Role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases DOI Open Access

Grecu Ramona Cătălina,

Victor Gheorman,

Veronica Gheorman

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(7), P. 837 - 837

Published: April 7, 2025

Psychiatric disorders and internal diseases frequently co-occur, posing significant challenges due to overlapping symptoms, shared pathophysiological mechanisms, increased healthcare burdens. Neuroinflammation has emerged as a central mechanism linking these conditions, driven by systemic inflammation, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, autonomic nervous system (ANS) imbalance. This review synthesizes current evidence on the role of neuroinflammation in comorbid conditions such depression, anxiety, cardiovascular disease, diabetes mellitus, emphasizing bidirectional relationships inflammatory pathways. analysis identifies gaps longitudinal studies, biomarker validation, integration multidisciplinary care models. Emerging therapeutic approaches, including IL-6 inhibitors, vagus nerve stimulation, behavioral interventions, show promise but remain underexplored combined applications. Furthermore, disparities research representation limit generalizability findings highlight need for inclusive clinical trials. Addressing through precision medicine, advanced monitoring technologies, equitable strategies could transform management complex comorbidities. By advancing our understanding neuroinflammatory mechanisms promoting integrated this underscores collaborative, patient-centered approach improve outcomes reduce global burden psychiatric disease

Language: Английский

Associations between internal exposure to acrylamide and sleep health: evidence from NHANES 2013–2016 DOI Creative Commons
Lin Gan,

Jiaoyang Wang,

Kang Qu

et al.

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 19, 2025

Acrylamide (AA) is a ubiquitous neurotoxic contaminant. Our objectives were to evaluate associations of internal AA exposure with sleep health outcomes. Data from 2753 adults aged 20–79 years in the National Health and Nutrition Examination Survey (NHANES) was utilized. Internal assessed using hemoglobin adducts urinary biomarkers. Short duration (SSD) self-reported trouble sleeping employed as indicators health. Markers systemic inflammation calculated. Each one-unit increase ln-transformed acrylamide (HbAA), glycidamide (HbGA) HbAA + HbGA creatinine-adjusted N-Acetyl-S-(2-carbamoylethyl)-L-cysteine concentration statistically significantly associated 1.37-fold (95% confidence interval [CI]: 1.16, 1.62; p = 0.002), 1.41-fold (95%CI: 1.19, 1.68; 1.43-fold 1.70; 0.001), 1.24-fold 1.08, 1.42; 0.007) risk SSD, respectively. The significant strengthened smokers after stratification by smoking status. Higher biomarkers predicted increases markers inflammation. In conclusion, an increased SSD elevated among United States adults. findings shed light on potential effects AA's threat future research warranted develop intervention strategies.

Language: Английский

Citations

0
Association between RAR and the prevalence and prognosis of depression: A population-based study DOI
Xiaofeng Zhu, Yuqi Hu, Zhiwei Long

et al.

Journal of Affective Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
The Role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases DOI Open Access

Grecu Ramona Cătălina,

Victor Gheorman,

Veronica Gheorman

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(7), P. 837 - 837

Published: April 7, 2025

Psychiatric disorders and internal diseases frequently co-occur, posing significant challenges due to overlapping symptoms, shared pathophysiological mechanisms, increased healthcare burdens. Neuroinflammation has emerged as a central mechanism linking these conditions, driven by systemic inflammation, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, autonomic nervous system (ANS) imbalance. This review synthesizes current evidence on the role of neuroinflammation in comorbid conditions such depression, anxiety, cardiovascular disease, diabetes mellitus, emphasizing bidirectional relationships inflammatory pathways. analysis identifies gaps longitudinal studies, biomarker validation, integration multidisciplinary care models. Emerging therapeutic approaches, including IL-6 inhibitors, vagus nerve stimulation, behavioral interventions, show promise but remain underexplored combined applications. Furthermore, disparities research representation limit generalizability findings highlight need for inclusive clinical trials. Addressing through precision medicine, advanced monitoring technologies, equitable strategies could transform management complex comorbidities. By advancing our understanding neuroinflammatory mechanisms promoting integrated this underscores collaborative, patient-centered approach improve outcomes reduce global burden psychiatric disease

Language: Английский

Citations

0